DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

TreatmentTrends: Advanced/Metastatic Breast Cancer US 2013

TreatmentTrends®: Advanced/Metastatic Breast Cancer (U.S.) examines the current trends in the management of advanced/metastatic breast cancer in the United States from the perspective of surveyed medical oncologists.
This report series provides the opportunity to gain greater understanding of medical practice patterns in breast cancer by disease setting, physicians’ perceptions of brands and specific product attributes, and the impact of sales and messaging efforts.

Questions Answered in This Report:

  • Determine the most important issues in the treatment of advanced/metastatic breast cancer and how they are being met by the currently available products used by medical oncologists

  • Understand current treatment rates and patient shares in different breast cancer treatment populations and settings, as reported by sur-veyed physicians

  • Collect information on the promotional messages and activities target-ing medical oncologists

  • Capture interest and anticipated value of therapies in development for advanced/metastatic cancer

  • Understand the expected use of emerging therapies and the threats these emerging therapies pose to currently available treatments


Sample Frame & Methodology:

100 medical oncologists complete a 60-minute online quantitative survey with several open-ended questions for qualitative feedback.

To qualify, respondents must meet the following criteria:

- Minimum of 25 Breast cancer patients under management per month

- Have been in practice a minimum of 2 years and a maximum of 30 years

- More than 75 percent of professional time spent in clinical practice (academic hospital setting allowed 50 percent practice time)


- Final report in PowerPoint format

- Access to author

Key Drugs Covered:

Herceptin, Perjeta, Kadcyla, Tykerb, Abraxane, paclitaxel, docetaxel, Xeloda, Afinitor, anastrozole, letro-zole, exemestane, Faslodex

Related Reports:

LaunchTrends®: Perjeta and Kadcyla (US)

Pharmacor®: Breast Cancer

DecisionBase®: Breast Cancer (Advanced/metastatic HR+/HER2-)

PatientBase®: Breast Cancer in G7, Brazil, Russia, India, China, Mexico, Turkey, and South Korea

Physician and Payer Forum® (Emerging Markets): Breast Cancer in Chi-na and South Korea: Physician and Payer Insight into Market Access Drivers

Physician and Payer Forum® (EU5): Tightening Healthcare Budgets and Elevated Cost-Effectiveness Expectations: How Will Payers and Prescrib-ers Proiritize Targeted Agents for Breast Cancer in the EU5?